|
|
|
CONDOR: Study of 18F-DCFPyL PET/CT Imaging in Patients with Suspected Recurrence of Prostate Cancer
|
|
Michael J. Morris, MD
|
| Michael Morris, Oliver Sartor, and Alicia Morgans discuss the CONDOR study, the second of two prospective clinical trials designed in collaboration with the FDA to demonstrate the diagnostic performance of PyL in patients with biochemically recurrent prostate cancer.
|
|
|
|
|
|
|
|
|
|
|
|
|
Best of ASCO 2020 Prostate Cancer
|
|
A. Oliver Sartor, MD
|
| Oliver Sartor joins Alicia Morgans to speak about several prostate cancer studies making an impact on the diagnosis of prostate cancer and the treatment paradigm for this disease.
|
|
|
|
|
|
|
|
|
|
|
|
|
TheraP: 177Lu-PSMA617 Theranostic vs Cabazitaxel in Progressive Metastatic Castration Resistant Prostate Cancer (mCRPC)
|
|
Ian Davis, MBBS, Ph.D. FRACP
|
| Ian Davis and Michael Hofman discuss the TheraP trial with Alicia Morgans which was presented at the ASCO 2020 virtual meeting.
|
|
|
|
|
|
|
|
|
|
|
|
|
Alpha Particles as Radiopharmaceuticals in the Treatment of Bone Metastases
|
A. Oliver Sartor, MD
Neal Shore and Oliver Sartor discuss the role of both alpha and beta radiopharmaceuticals that are on the horizon for treatment of bone metastases in prostate cancer.
|
|
|
|
|
|
|
|
|
|
|
|
The VISION Trial: Radionuclide Therapy Plus Standard Therapy for Metastatic Castration Resistant Prostate Cancer
|
A. Oliver Sartor, MD, and Michael J. Morris, MD
At the 26th Annual Prostate Cancer Foundation Scientific Retreat, Oliver Sartor and Michael Morris join Charles Ryan to discuss lutetium in advanced prostate cancer and the VISION trial.
|
|
|
|
|
|
|
|
|
|
|
|
The Use of Novel Imaging Methods in Prostate Cancer
|
Stefano Fanti, MD
Stefano Fanti joins Phillip Koo to discuss the use of novel imaging methods in the prostate cancer space. Their discussion highlights the excitement and limitations around imaging including the methods of MRI and PET, and its impacts on patient care.
|
|
|
|
|
|
|
|
|
| Dosing of Initial Patients in Phase 3 SPOTLIGHT Clinical Trial of Targeted PET Imaging Agent rhPSMA-7.3 (18F) in Biochemically Recurrent Prostate Cancer
|
| Press Release
|
| Blue Earth Diagnostics, a Bracco company focused on molecular imaging diagnostics, announced that the first patients have been dosed at clinical trial sites in its Phase 3 SPOTLIGHT clinical trial of rhPSMA-7.3 (18F), an investigational Prostate-Specific Membrane Antigen-targeted radiohybrid PET imaging agent.
|
|
|
|
|
|
| Accuracy of 68Ga-PSMA-11 for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection
|
| Thomas Hope, MD
|
| In the presented prospective multicenter single-arm open-label phase 3 imaging trial, the authors aimed to determine the accuracy of 68-GA-PSMA-11 PET for the detection of pelvic nodal metastasis compared to histopathology at time of radical prostatectomy.
|
|
|
|
|
|
|
|
|
|
|
| CONDOR: The Impact of PSMA-targeted Imaging with 18F-DCFPyL-PET/CT on Clinical Management of Patients with Biochemically Recurrent Prostate Cancer
|
| Michael J. Morris, MD
|
| This study evaluates how PyL PET/CT may change clinical management for these men with biochemical recurrence. 208 men with a median PSA of 0.8 underwent PyL PET/CT. The inclusion criteria and exclusion criteria are shown below. The PSA had to be ≥0.2 ng/mL in the post-RP patient and ≥2.0 ng/mL in the post-RT or cryotherapy patient.
|
|
|
|
|
|
|
